Integrative analysis of prostate cancer aggressiveness

Prostate

Volumn 73, Issue 13, 2013, Pages 1413-1426

  Feik, Elisabeth ^a   Schweifer, Norbert ^b   Baierl, Andreas ^c   Sommergruber, Wolfgang ^b   Haslinger, Christian ^b   Hofer, Philipp ^a   Maj Hes, Agnes ^d   Madersbacher, Stephan ^e   Gsur, Andrea ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e DANUBE HOSPITAL   (Austria)

Author keywords

biomarker; copy number alteration; gene expression; prostate cancer outcome

Indexed keywords

MESSENGER RNA;

ADULT; AGED; AGGRESSIVENESS; ARTICLE; CANCER GROWTH; CELL POPULATION; CHROMOSOME DELETION; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

BIOMARKER; COPY NUMBER ALTERATION; GENE EXPRESSION; PROSTATE CANCER OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84882242603     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22688     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893-2917.
2. Vutuc C, Schernhammer ES, Haidinger G, Waldhor T,. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr 2005; 117 (13-14): 457-461.
3. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL,. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113 (6): 913-923.
4. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A,. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int 2012; 109 (Suppl. 2): 1-7.
5. Schaid DJ,. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 (Spec No 1): R103-R121.
6. Nakagawa H, Akamatsu S, Takata R, Takahashi A, Kubo M, Nakamura Y,. Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Sci 2012; 103 (4): 607-613.
7. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI,. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361 (9361): 955-964.
8. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101 (3): 811-816.
9. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR,. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67 (18): 8504-8510.
10. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007; 67 (17): 8229-8239.
11. Jiang M, Li M, Fu X, Huang Y, Qian H, Sun R, Mao Y, Xie Y,., Li Y,. Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray. Prostate 2008; 68 (14): 1496-1509.
12. Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, Yu JZ, Dash A, Jean-Gilles J, Reuter V, Gerald WL, Lee P, Osman I,. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010; 8: 70.
13. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
14. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51.
15. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, Schaeffer EM,. Gene expression pathways of high grade localized prostate cancer. Prostate 2011; 71: 1568-1578.
16. Watzinger F, Lion T,. Multiplex PCR for quality control of template RNA/cDNA in RT-PCR assays. Leukemia 1998; 12 (12): 1984-1986; discussion 1987-1993.
17. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP,. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4 (2): 249-264.
18. Bengtsson H, Irizarry R, Carvalho B, Speed TP,. Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics (Oxford, England) 2008; 24 (6): 759-767.
19. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E,. Analysis of array CGH data: From signal ratio to gain and loss of DNA regions. Bioinformatics (Oxford, England) 2004; 20 (18): 3413-3422.
20. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N,. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2 (5): 401-404.
21. Pinkel D, Albertson DG,. Array comparative genomic hybridization and its applications in cancer. Nat Genet 2005; 37 (Suppl): S11-S17.
22. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J,. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies. Prostate 2007; 67 (7): 692-700.
23. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB,. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91 (18): 1574-1580.
24. Choucair KA, Guerard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J,. The 16p13.3 (PDPK1) genomic gain in prostate cancer: A potential role in disease progression. Transl Oncol 2012; 5 (6): 453-460.
25. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW,. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95 (1): 29-39.
26. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD,. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011; 21 (1): 47-55.
27. Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, Nakamura Y, Inazawa J,. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 2007; 26 (8): 1110-1121.
28. Bullinger L, Kronke J, Schon C, Radtke I, Urlbauer K, Botzenhardt U, Gaidzik V, Cario A, Senger C, Schlenk RF, Downing JR, Holzmann K, Dohner K, Dohner H,. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 2010; 24 (2): 438-449.
29. Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R,. RYBP stabilizes p53 by modulating MDM2. EMBO Rep 2009; 10 (2): 166-172.
30. Castrillon DH, Quade BJ, Wang TY, Quigley C, Crum CP,. The human VASA gene is specifically expressed in the germ cell lineage. Proc Natl Acad Sci USA 2000; 97 (17): 9585-9590.
31. Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ III, Thor AD, Benz CC,. Ets regulation of the erbB2 promoter. Oncogene 2000; 19 (55): 6490-6502.
32. Huang X, Brown C, Ni W, Maynard E, Rigby AC, Oettgen P,. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107 (8): 3153-3160.
33. Tzenov YR, Andrews PG, Voisey K, Popadiuk P, Xiong J, Popadiuk C, Kao KR,. Human papilloma virus (HPV) E7-mediated attenuation of retinoblastoma (Rb) induces hPygopus2 expression via Elf-1 in cervical cancer. Mol Cancer Res 2013; 11 (1): 19-30.
34. Gerloff A, Dittmer A, Oerlecke I, Holzhausen HJ, Dittmer J,. Protein expression of the Ets transcription factor Elf-1 in breast cancer cells is negatively correlated with histological grading, but not with clinical outcome. Oncol Rep 2011; 26 (5): 1121-1125.
35. Yang DX, Li NE, Ma Y, Han YC, Shi Y,. Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density. Chin J Cancer 2010; 29 (4): 396-402.
36. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP,. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55 (2): 342-347.
37. Steiner T, Junker K, Burkhardt F, Braunsdorf A, Janitzky V, Schubert J,. Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer. Eur Urol 2002; 41 (2): 167-171.
38. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B,. A phosphatase associated with metastasis of colorectal cancer. Science (New York, NY) 2001; 294 (5545): 1343-1346.
39. Peng L, Ning J, Meng L, Shou C,. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 2004; 130 (9): 521-526.
40. Radke I, Gotte M, Kersting C, Mattsson B, Kiesel L, Wulfing P,. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer 2006; 95 (3): 347-354.
41. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A, Broggini M,. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 2005; 11 (19 Pt 1): 6835-6839.
42. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara K, Yokozaki H,. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: An in situ hybridization study. Virchows Arch 2007; 450 (3): 303-310.